[HTML][HTML] Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection

AWH Chan, J Zhong, S Berhane, H Toyoda… - Journal of …, 2018 - Elsevier
Background & Aims Resection is the most widely used potentially curative treatment for
patients with early hepatocellular carcinoma (HCC). However, recurrence within 2 years …

Systemic therapies for hepatocellular carcinoma

S Ge, D Huang - Drug Discoveries & Therapeutics, 2015 - jstage.jst.go.jp
Hepatocellular carcinoma (HCC) is a common cancer with high incidence and mortality
worldwide. The main treatments for HCC include radical hepatectomy, liver transplant …

A GYS2/p53 negative feedback loop restricts tumor growth in HBV-related hepatocellular carcinoma

SL Chen, CZ Zhang, LL Liu, SX Lu, YH Pan, CH Wang… - Cancer research, 2019 - AACR
Hepatocellular carcinogenesis is attributed to the reprogramming of cellular metabolism as a
consequence of the alteration in metabolite-related gene regulation. Identifying the …

Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence

M Pazgan-Simon, KA Simon, E Jarowicz… - Clinical and …, 2018 - termedia.pl
Chronic hepatitis B virus (HBV) infection and HBV-related liver disease are estimated to
affect about 240 million people worldwide. Now that a vaccine is available, the number of …

Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction

J Yang, WW Xu, P Hong, F Ye, XH Huang, HF Hu… - Cancer letters, 2019 - Elsevier
Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma
but not in colon cancer, and the mechanism of vemurafenib resistance remains unclear. In …

[HTML][HTML] Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment: a …

J Wu, Z Yin, L Cao, X Xu, T Yan, C Liu, D Li - Medicine, 2018 - journals.lww.com
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers and the
second leading cause of cancer-related deaths in men worldwide. Surgical resection of …

Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma

H Takeyama, T Beppu, T Higashi, T Kaida, K Arima… - Surgery Today, 2018 - Springer
Background For advanced hepatocellular carcinoma (HCC), surgical treatment after
sorafenib induction has rarely been reported. We examined the survival benefit of additional …

[HTML][HTML] The comparison of different antiviral therapies on the prognosis of hepatitis B virus-related hepatocellular carcinoma after curative treatments: A network meta …

Z Xia, L He, L Xiong, T Wen - Medicine, 2020 - journals.lww.com
Objective: The purpose of this study was to evaluate the efficacy of different nucleos (t) ide
analogues in the prognosis of HBV-related hepatocellular carcinoma (HCC) patients after …

Efficacy of nucleoside analogs for chronic hepatitis B virus-related hepatocellular carcinoma after curative treatment: a meta-analysis

G Zhang, X Yu, P Liu, X Huang, X Jiang - Digestive Diseases and …, 2018 - Springer
Abstract Background and Aim The efficacy of nucleoside analogs (NAs) for hepatitis B virus
(HBV)-related hepatocellular carcinoma (HCC) after curative treatment remains unclear. The …

[HTML][HTML] Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study

MH Su, AL Lu, SH Li, SH Zhong, BJ Wang… - World journal of …, 2015 - ncbi.nlm.nih.gov
AIM: To investigate clinical outcomes of chronic hepatitis B (CHB) and liver cirrhosis (LC)
patients under whole-course management with lamivudine (LAM). METHODS: This was a …